相关实验视频

Updated: May 17, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

针对转移性结肠直肠癌患者的KRAS瘤基因

Ruoyu Miao¹, James Yu², Richard D Kim²

¹Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.

|May 14, 2025

概括

KRAS突变驱动着结直肠癌 (CRC) 和对治疗的耐药性. 新的KRAS G12C抑制剂显示出希望,但组合策略和免疫疗法为治疗这种常见恶性瘤提供了更广泛的潜力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症遗传学癌症遗传学

背景情况:

结肠直肠癌 (CRC) 是全球普遍存在的恶性瘤,在约40%的病例中发现了KRAS突变.
激活KRAS突变可以促进瘤发生,并通过失调MAPK和PI3K-AKT-mTOR等关键信号通路来产生对治疗的抗性.
目前的治疗策略面临由于内异质性和新兴的抵抗机制的局限性.

研究的目的:

为提供KRAS突变结直肠癌的全面审查.
讨论驱动CRC瘤发生和治疗耐药性的分子机制.
探索当前和新兴的治疗策略和管理KRAS突变CRC的挑战.

主要方法:

在KRAS突变CRC中的分子机制的文献综述.
分析当前的治疗进展,包括KRAS G12C抑制剂和组合策略.
探索新兴的免疫疗法方法和挑战.

主要成果:

克拉斯G12C抑制剂 (索托拉西布,阿达格拉西布) 在克拉斯突变CRC的一个子集中显示出临床疗效.
组合疗法 (例如,KRAS抑制剂与抗EGFR药物) 正在研究中.
瘤微环境为免疫治疗提供了新的点,包括新抗原疫苗和T细胞疗法.

结论:

针对性治疗和组合策略为特定的KRAS突变CRC患者提供了更好的结果.
针对瘤微环境的免疫疗法方法对未来的CRC治疗具有重大潜力.
解决诸如内异质性和非G12C突变等挑战对于推进CRC管理至关重要.

关键词:

克拉斯 (Kras) 是一个国家.结肠直肠癌是什么意思突变是一种突变.电阻的阻力可以有针对性的治疗.

更多相关视频

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...